EA201491666A1 - Способы повышения устойчивости скелетных мышц к утомлению - Google Patents

Способы повышения устойчивости скелетных мышц к утомлению

Info

Publication number
EA201491666A1
EA201491666A1 EA201491666A EA201491666A EA201491666A1 EA 201491666 A1 EA201491666 A1 EA 201491666A1 EA 201491666 A EA201491666 A EA 201491666A EA 201491666 A EA201491666 A EA 201491666A EA 201491666 A1 EA201491666 A1 EA 201491666A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatigue
skeletal muscles
increasing
ways
stability
Prior art date
Application number
EA201491666A
Other languages
English (en)
Other versions
EA032480B1 (ru
Inventor
Фейди Малик
Джеффри Р. Джаспер
Адам Кеннеди
Даррен Хвее
Original Assignee
Сайтокинетикс, Инк.
Фейди Малик
Джеффри Р. Джаспер
Адам Кеннеди
Даррен Хвее
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайтокинетикс, Инк., Фейди Малик, Джеффри Р. Джаспер, Адам Кеннеди, Даррен Хвее filed Critical Сайтокинетикс, Инк.
Publication of EA201491666A1 publication Critical patent/EA201491666A1/ru
Publication of EA032480B1 publication Critical patent/EA032480B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложены соединения, композиции и способы повышения устойчивости скелетных мышц к утомлению, включающие введение эффективного количества активатора тропонина скелетных мышц. Также предложены способы повышения устойчивости к утомлению, повышения физической выносливости или снижения непереносимости физической нагрузки у субъекта, имеющего патологическое состояние, связанное с мышечным утомлением или слабостью, например, такое как сердечная недостаточность.
EA201491666A 2012-04-11 2013-04-11 Способы повышения устойчивости скелетных мышц к утомлению EA032480B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US201261735809P 2012-12-11 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (2)

Publication Number Publication Date
EA201491666A1 true EA201491666A1 (ru) 2015-03-31
EA032480B1 EA032480B1 (ru) 2019-06-28

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491666A EA032480B1 (ru) 2012-04-11 2013-04-11 Способы повышения устойчивости скелетных мышц к утомлению

Country Status (15)

Country Link
US (2) US20150250784A1 (ru)
EP (1) EP2836590A4 (ru)
JP (2) JP6352244B2 (ru)
KR (1) KR102163931B1 (ru)
CN (2) CN104395458A (ru)
AU (3) AU2013245917A1 (ru)
BR (1) BR112014025251B1 (ru)
CA (1) CA2869675C (ru)
EA (1) EA032480B1 (ru)
HK (1) HK1206389A1 (ru)
IL (2) IL234886A (ru)
MX (1) MX2014012179A (ru)
PH (1) PH12014502286A1 (ru)
SG (2) SG10201704166RA (ru)
WO (1) WO2013155262A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
IN2014DN00200A (ru) 2011-07-13 2015-06-05 Cytokinetics Inc
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
SI3137622T1 (sl) * 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
ES2750751T3 (es) * 2014-09-09 2020-03-27 Astellas Pharma Inc Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria
TWI773118B (zh) 2016-02-12 2022-08-01 美商細胞動力學股份有限公司 四氫異喹啉衍生物
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN116635378A (zh) 2020-11-06 2023-08-22 赛特凯恩蒂克公司 二环1,4-二氮杂环庚酮和其治疗用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
SI2069352T1 (sl) * 2006-08-02 2013-12-31 Cytokinetics, Inc. Določene kemijske entitete, sestavki in postopki
US7989469B2 (en) * 2008-02-04 2011-08-02 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CN108553467A (zh) * 2012-04-02 2018-09-21 赛特凯恩蒂克公司 改善膈肌功能的方法

Also Published As

Publication number Publication date
CA2869675C (en) 2022-06-14
IL234886A (en) 2017-02-28
MX2014012179A (es) 2015-07-14
BR112014025251B1 (pt) 2021-03-02
CN111840294A (zh) 2020-10-30
SG10201704166RA (en) 2017-06-29
PH12014502286B1 (en) 2014-12-15
IL250473A0 (en) 2017-03-30
HK1206389A1 (en) 2016-01-08
CN104395458A (zh) 2015-03-04
AU2019268177A1 (en) 2019-12-12
KR102163931B1 (ko) 2020-10-12
WO2013155262A3 (en) 2013-12-27
AU2013245917A1 (en) 2014-10-23
JP2018048209A (ja) 2018-03-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
AU2018200930A1 (en) 2018-03-01
EP2836590A4 (en) 2016-04-13
WO2013155262A2 (en) 2013-10-17
KR20160046694A (ko) 2016-04-29
CA2869675A1 (en) 2013-10-17
JP6352244B2 (ja) 2018-07-04
JP6535727B2 (ja) 2019-06-26
JP2015516392A (ja) 2015-06-11
US20150250784A1 (en) 2015-09-10
US20190167676A1 (en) 2019-06-06
SG11201406359TA (en) 2014-11-27
PH12014502286A1 (en) 2014-12-15

Similar Documents

Publication Publication Date Title
EA201491666A1 (ru) Способы повышения устойчивости скелетных мышц к утомлению
PH12014502217A1 (en) Methods for improving diaphragm function
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
EA202090946A2 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
EA201101519A1 (ru) Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
ECSP11010905A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201492160A1 (ru) Композиции, содержащие бензодиазепины короткого действия
EA201400579A1 (ru) Антитела к il-36r
MX2012008440A (es) Tratamiento de enfermedades cardiacas.
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
BR112014031412A2 (pt) método de preparação de uma composição, composição e seu uso, e kit.
CY1124995T1 (el) Μεθοδοι για τη μειωση της εκπτωσης στη ζωτικη χωρητικοτητα
MY183872A (en) Low water drying type joint compound
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
NZ701463A (en) Anti-phytopathogenic composition
FR3012462B1 (fr) Compositions stables de poly (3,4-ethylenedioxythiophene) et de stabilisants anioniques a acidite limitee
FR2977256B1 (fr) Compositions de 2,4,4,4-tetrafluorobut-1-ene et de cis-1,1,1,4,4,4-hexafluorobut-2-ene
PH12014501176A1 (en) Anticoagulant reversal agents
BR112015011759A2 (pt) composição simbiótica e uso da mesma
EA201791318A1 (ru) Дрожжи для приготовления алкогольных напитков

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM